Circumvention of cytarabine (Ara-C) resistance by 2-chloro-deoxyadenosine (2-CdA) in pediatric acute myeloid (AML) and acute lymphoblastic (ALL) leukemia: An in vitro study.

被引：0
|
作者：
Zwaan, CM
Kaspers, GJL
Pieters, R
Huismans, DR
Van Wering, ER
Janka-Schaub, GE
Creutzig, U
Henze, G
Veerman, AJP
机构：
[1] Vrije Univ Amsterdam, Univ Hosp Amsterdam, Dept Pediat Hematol Oncol, Amsterdam, Netherlands
[2] Sophia Childrens Hosp, Dept Hematol Oncol, Rotterdam, Netherlands
[3] Dutch Childhood Leukemia Study Grp, The Hague, Netherlands
[4] CoALL Study Grp, Hamburg, Germany
[5] AML BFM Study Grp, Munster, Germany
[6] BFM ALL Relapse Study Grp, Berlin, Germany
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1327
引用
收藏
页码：307A / 307A
页数：1
相关论文
共 50 条
  • [1] Interim analysis of cytarabine (ara-C) and cladribine (2-CDA) combination therapy in acute myeloid leukemia (AML).
    Radomski, KM
    Gandhi, V
    Srivastava, DK
    Razzouk, BI
    Behm, FG
    Plunkett, W
    Pui, CH
    Rubnitz, JE
    Ribeiro, RC
    BLOOD, 2000, 96 (11) : 327A - 327A
  • [2] CLADRIBINE(2-CDA) AND CYTARABINE(ARA-C) IS AN EFFECTIVE SALVAGE REGIMEN IN REFRACTORY/RELAPSED ACUTE MYELOID LEUKAEMIA IN CHILDREN
    Chinnaswamy, Girish
    Prasad, Maya
    Dwivedi, Pankaj
    Patil, Vijay
    Arora, Brijesh
    Banavali, Shripad
    PEDIATRIC BLOOD & CANCER, 2012, 59 (06) : 1040 - 1040
  • [3] 2-chloro-deoxyadenosine (cladribine) to circumvent cytarabine resistance in vitro in childhood leukemia.
    Kaspers, GJL
    Zwaan, CM
    Pieters, R
    Ramakers-Van Woerden, NL
    Van Wering, ER
    Janka-Schaub, GE
    Creutzig, U
    Henze, G
    Veerman, AJP
    CLINICAL CANCER RESEARCH, 2000, 6 : 4506S - 4506S
  • [4] Factors associated with hematologic response to 2 chloro-deoxyadenosine (2-CDA) in de novo pediatric acute myeloid leukemia.
    Ribeiro, RC
    Santana, VM
    Head, D
    Jayawardene, D
    Srivastava, DK
    Raimondi, S
    Hurwitz, CA
    Mahmoud, H
    Krance, R
    BLOOD, 1996, 88 (10) : 866 - 866
  • [5] Irinotecan (CPT-11) and cytarabine (Ara-C) in refractory acute myeloid leukemia (AML).
    Minderman, H
    O'Loughlin, KL
    Thomas, KJ
    Pixley, LA
    Wetzler, M
    Slack, JL
    Baer, MR
    LEUKEMIA, 2001, 15 (03) : 509 - 509
  • [6] CURATIVE EFFECT AND SAFETY OF 2-CDA, ARA-C AND G-CSF COMBINED TREATMENT FOR RELAPSED REFRACTORY ACUTE MYELOID LEUKEMIA
    Zhang, Xiaoxiang
    Chen, Ying
    Shou, Lihong
    Yang, Jianghua
    ACTA MEDICA MEDITERRANEA, 2021, 37 (01): : 163 - 167
  • [7] Cladribine (2-CDA) in combination with Ara-C. Etoposide and G-CSF is effective in secondary or relapsed acute myeloid leukemia (AML).
    Krieger, O
    Kasparu, H
    Girschikofsky, M
    Lutz, D
    BLOOD, 1996, 88 (10) : 3422 - 3422
  • [8] LOW-DOSE CYTARABINE (ARA-C) IN THE TREATMENT OF MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID-LEUKEMIA (AML)
    MUFTI, GJ
    OSCIER, DG
    HAMBLIN, TJ
    BRITISH JOURNAL OF HAEMATOLOGY, 1985, 61 (03) : 571 - 571
  • [9] A phase I/II study of idarubicin (Ida) with continuous infusion fludarabine (F-ara-A) and cytarabine (ara-C) for refractory or recurrent pediatric acute myeloid leukemia (AML)
    Leahey, A
    Kelly, K
    Rorke, LB
    Lange, B
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 1997, 19 (04) : 304 - 308
  • [10] PHASE 1B RESULTS OF IDASANUTLIN plus CYTARABINE (ARA-C) IN ACUTE MYELOID LEUKEMIA (AML) PATIENTS (PTS)
    Martinelli, G.
    Pappayannidis, C.
    Yee, K.
    Vey, N.
    Drummond, M.
    Kelly, K.
    Dickinson, M.
    Lee, J. H.
    Seiter, K.
    Yoon, S. S.
    Assouline, S.
    Kasner, M.
    Nichols, G.
    Middleton, S.
    Blotner, S.
    Zhi, J.
    Pierceall, W.
    Chen, L. C.
    HAEMATOLOGICA, 2016, 101 : 187 - 187
12345